Just yesterday, NRx’s stock was at $10.11. However, today it is gaining momentum: the price is currently at $12.11, resulting in a 20% gain. The company announced today it has legalized the first commercial formulation of ZYESAMI™ for intravenous use, allowing for big volume manufacture, with an anticipated one or greater year stability, under required storage conditions.
At the same time, NRx has achieved a 30-to-50-fold rise in its manufactured lot size of aviptadil, with a concurrent 90% reduction in the cost of its peptide supply. These two developments allow NRx to potentially deliver millions of doses of ZYESAMI™ as potential regulatory approvals are obtained in regions worldwide.
As the Delta and more variants threatening, newer mutations of the Coronavirus continue to destroy the immunity created by first-generation vaccines, NRx is in active contact with national health departments regarding Emergency Use Authorization for ZYESAMI. The new formulation allows for immediate shipping internationally, upon potential EUA approval.
Agneta is still enjoying her trips to Asia and Africa while she works at Own Snap as an author and reporter. Very soon she will settle somewhere in Europe and run her startup enterprise.